N. Martynova, N. Vorobyov, K. Boyko, Yu. V. Gutsalo, M. Linnik, K. Suprun, G. Andreev, A. Lyubinskiy, E. Spiridenko, A. Kalesnik
{"title":"以sergey berezin命名的国际生物系统研究所治疗和诊断中心的质子治疗经验:反复颅脊髓照射治疗复发性髓母细胞瘤儿科患者","authors":"N. Martynova, N. Vorobyov, K. Boyko, Yu. V. Gutsalo, M. Linnik, K. Suprun, G. Andreev, A. Lyubinskiy, E. Spiridenko, A. Kalesnik","doi":"10.24110/0031-403x-2023-102-3-50-57","DOIUrl":null,"url":null,"abstract":"Repeated craniospinal irradiation (CSR) is one of the options in the treatment of multifocal recurrences of medulloblastomas (MB), however, it is prescribed to a limited extent due to its toxicity. The use of proton therapy can reduce the toxicity of treatment. Materials and methods used: a single-center retrospective cohort study was conducted in 25 patients (18 (72%) boys/7 (28%) girls) aged 7 to 18 y/o (median 13 (10-14) y/o) in 2019-2023. Repeated CSR was performed for leptomeningeal MB recurrence using a proton beam at the Treatment and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin (Saint Petersburg, Russia). The median dose of primary CSR was 35.2 Gy (24-35.2). The median dose of repeated CSR was 30.6 Gy (24-35.2). 23 patients after CSR were given a local boost on the area of metastatic lesions and local recurrence (if any). 7 had previously received courses of repeated radiation therapy for recurrent MB. Results: during the course of the treatment thrombocytopenia was noted with a statistically significant decrease by the 3rd week of treatment (M=97x109/l, p<0.001). The median follow-up was 12.5 months (8-19.5). In 8 patients, progression of the disease was observed, which resulted in the death of 7 of them. In one patient, the appearance of radiation necrosis in the local boost area (left cerebellar peduncle) was noted 5 months after the completion of the repeated irradiation course. The median progression period was 17 months (95% CI 10.8-23.1). Conclusions: proton therapy makes it possible to deliver therapeutic doses for CSR with an acceptable level of hematological toxicity. The obtained data on relapse-free and overall survival indicate the need for further study of the role of repeated CSR and the development of a methodology for calculating the permissible maximum effective dose during the repeated exposure.","PeriodicalId":39654,"journal":{"name":"Pediatriya - Zhurnal im G.N. Speranskogo","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"REPEATED CRANIOSPINAL IRRADIATION IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA: PROTON THERAPY EXPERIENCE AT THE TREATMENT AND DIAGNOSTIC CENTER OF THE INTERNATIONAL INSTITUTE OF BIOLOGICAL SYSTEMS NAMED AFTER SERGEY BEREZIN\",\"authors\":\"N. Martynova, N. Vorobyov, K. Boyko, Yu. V. Gutsalo, M. Linnik, K. Suprun, G. Andreev, A. Lyubinskiy, E. Spiridenko, A. Kalesnik\",\"doi\":\"10.24110/0031-403x-2023-102-3-50-57\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Repeated craniospinal irradiation (CSR) is one of the options in the treatment of multifocal recurrences of medulloblastomas (MB), however, it is prescribed to a limited extent due to its toxicity. The use of proton therapy can reduce the toxicity of treatment. Materials and methods used: a single-center retrospective cohort study was conducted in 25 patients (18 (72%) boys/7 (28%) girls) aged 7 to 18 y/o (median 13 (10-14) y/o) in 2019-2023. Repeated CSR was performed for leptomeningeal MB recurrence using a proton beam at the Treatment and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin (Saint Petersburg, Russia). The median dose of primary CSR was 35.2 Gy (24-35.2). The median dose of repeated CSR was 30.6 Gy (24-35.2). 23 patients after CSR were given a local boost on the area of metastatic lesions and local recurrence (if any). 7 had previously received courses of repeated radiation therapy for recurrent MB. Results: during the course of the treatment thrombocytopenia was noted with a statistically significant decrease by the 3rd week of treatment (M=97x109/l, p<0.001). The median follow-up was 12.5 months (8-19.5). In 8 patients, progression of the disease was observed, which resulted in the death of 7 of them. In one patient, the appearance of radiation necrosis in the local boost area (left cerebellar peduncle) was noted 5 months after the completion of the repeated irradiation course. The median progression period was 17 months (95% CI 10.8-23.1). Conclusions: proton therapy makes it possible to deliver therapeutic doses for CSR with an acceptable level of hematological toxicity. The obtained data on relapse-free and overall survival indicate the need for further study of the role of repeated CSR and the development of a methodology for calculating the permissible maximum effective dose during the repeated exposure.\",\"PeriodicalId\":39654,\"journal\":{\"name\":\"Pediatriya - Zhurnal im G.N. Speranskogo\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatriya - Zhurnal im G.N. Speranskogo\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24110/0031-403x-2023-102-3-50-57\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatriya - Zhurnal im G.N. Speranskogo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24110/0031-403x-2023-102-3-50-57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
反复颅脊髓照射(CSR)是治疗髓母细胞瘤(MB)多灶性复发的选择之一,但由于其毒性,其使用范围有限。使用质子治疗可以减少治疗的毒性。使用的材料和方法:在2019-2023年对25例患者(18例(72%)男孩/7例(28%)女孩)进行了单中心回顾性队列研究,年龄为7 - 18岁(中位数为13例(10-14)岁)。在Sergey Berezin(圣彼得堡,俄罗斯)命名的国际生物系统研究所治疗和诊断中心,使用质子束对脑膜轻脑膜MB复发进行重复CSR。原发性CSR的中位剂量为35.2 Gy(24-35.2)。重复CSR的中位剂量为30.6 Gy(24-35.2)。23例患者在CSR后给予局部增强转移灶和局部复发(如果有的话)的面积。结果:治疗过程中血小板减少,治疗第3周明显减少(M=97x109/l, p<0.001)。中位随访时间为12.5个月(8-19.5)。在8例患者中,观察到疾病进展,导致7例死亡。1例患者在重复放射治疗完成5个月后,局部增强区(左小脑脚)出现放射性坏死。中位进展期为17个月(95% CI 10.8-23.1)。结论:质子治疗使CSR的治疗剂量达到可接受的血液学毒性水平成为可能。获得的无复发和总生存期数据表明,需要进一步研究重复CSR的作用,并制定一种计算重复暴露期间允许的最大有效剂量的方法。
REPEATED CRANIOSPINAL IRRADIATION IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA: PROTON THERAPY EXPERIENCE AT THE TREATMENT AND DIAGNOSTIC CENTER OF THE INTERNATIONAL INSTITUTE OF BIOLOGICAL SYSTEMS NAMED AFTER SERGEY BEREZIN
Repeated craniospinal irradiation (CSR) is one of the options in the treatment of multifocal recurrences of medulloblastomas (MB), however, it is prescribed to a limited extent due to its toxicity. The use of proton therapy can reduce the toxicity of treatment. Materials and methods used: a single-center retrospective cohort study was conducted in 25 patients (18 (72%) boys/7 (28%) girls) aged 7 to 18 y/o (median 13 (10-14) y/o) in 2019-2023. Repeated CSR was performed for leptomeningeal MB recurrence using a proton beam at the Treatment and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin (Saint Petersburg, Russia). The median dose of primary CSR was 35.2 Gy (24-35.2). The median dose of repeated CSR was 30.6 Gy (24-35.2). 23 patients after CSR were given a local boost on the area of metastatic lesions and local recurrence (if any). 7 had previously received courses of repeated radiation therapy for recurrent MB. Results: during the course of the treatment thrombocytopenia was noted with a statistically significant decrease by the 3rd week of treatment (M=97x109/l, p<0.001). The median follow-up was 12.5 months (8-19.5). In 8 patients, progression of the disease was observed, which resulted in the death of 7 of them. In one patient, the appearance of radiation necrosis in the local boost area (left cerebellar peduncle) was noted 5 months after the completion of the repeated irradiation course. The median progression period was 17 months (95% CI 10.8-23.1). Conclusions: proton therapy makes it possible to deliver therapeutic doses for CSR with an acceptable level of hematological toxicity. The obtained data on relapse-free and overall survival indicate the need for further study of the role of repeated CSR and the development of a methodology for calculating the permissible maximum effective dose during the repeated exposure.
期刊介绍:
Journal “Pediatria” named after G.N. Speransky (the official short names of the Journal are “Journal «Pediatria»,” “Pediatria,” and “«Pediatria,» the Journal”) is the oldest Soviet-and-Russian (in the Russian Federation, the CIS and former Soviet Union) scientific and practical medical periodical assigned for pediatricians that is published continuously since May, 1922, and distributed worldwide. Our mission statement specifies that we aim to the ‘raising the level of skills and education of pediatricians, organizers of children’s health protection services, medicine scientists, lecturers and students of medical institutes for higher education, universities and colleges worldwide with an emphasis on Russian-speaking audience and specific, topical problems of children’s healthcare in Russia, the CIS, Baltic States and former Soviet Union Countries and their determination with the use of the World’s best practices in pediatrics.’ As part of this objective, the Editorial of the Journal «Pediatria» named after G.N. Speransky itself adopts a neutral position on issues treated within the Journal. The Journal serves to further academic discussions of topics, irrespective of their nature - whether religious, racial-, gender-based, environmental, ethical, political or other potentially or topically contentious subjects. The Journal is registered with the ISSN, - the international identifier for serials and other continuing resources, in the electronic and print world: ISSN 0031-403X (Print), and ISSN 1990-2182 (Online). The Journal was founded by the Academician, Dr. Georgiy Nestorovich SPERANSKY, in May, 1922. Now (since 1973) the Journal bears his honorary name.